Is Gilead Sciences' $32B Bet on AI Manufacturing and HIV Partnerships Transforming Its Investment Case (GILD)?

• Gilead Sciences recently broke ground on a 180,000-square-foot AI-enabled Pharmaceutical Development and Manufacturing Technical Development Center in Foster City as part of a US$32 billion investment plan through 2030, while also expanding global HIV prevention partnerships with PEPFAR to reach up to two million people by the end of 2025.
• This marks a significant move to integrate artificial intelligence and advanced technology into biologics manufacturing, underscoring Gilead’s ambition to accelerate therapeutic innovation and increase global health impact.
• We’ll explore how Gilead’s major investment in AI-powered manufacturing could influence its long-term earnings outlook and competitive position.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Gilead Sciences Investment Narrative Recap

To own Gilead Sciences stock, you need to believe the company can maintain leadership in HIV and innovate in high-growth areas like oncology, while navigating regulatory and pricing pressures. The recent announcement of Gilead's US$32 billion AI-enabled manufacturing expansion reflects its push for long-term operational efficiency and innovation, but does not directly affect the near-term catalyst of international HIV prevention launches or the principal risk of future pricing controls. At this stage, the impact is more strategic than immediate to revenue and risk outlook.

Of the latest developments, Gilead's partnership with PEPFAR to deliver lenacapavir for HIV prevention to two million people in underserved countries aligns directly with the short-term catalyst: expanding access to drive HIV franchise growth. This announcement is particularly relevant, as success in global PrEP access can help offset dependency on mature US markets, though it also highlights ongoing reimbursement and access risks in emerging geographies.

In contrast, investors should be aware that policy pressures on drug pricing may turn out to be far more significant...

Read the full narrative on Gilead Sciences (it's free!)

Gilead Sciences is projected to reach $32.3 billion in revenue and $10.0 billion in earnings by 2028. This outlook is based on an expected annual revenue growth rate of 3.8%, with earnings anticipated to rise by $3.7 billion from the current $6.3 billion.

Uncover how Gilead Sciences' forecasts yield a $124.91 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some analysts hold a much more optimistic view, pointing to Gilead's expanding HIV and oncology launches as key drivers for future growth. Before the recent news, the highest forecasts saw Gilead reaching US$33.9 billion in revenue and US$10.8 billion in earnings by 2028. These bullish estimates highlight how differing opinions can be, especially when important new information could shift the outlook. If you are weighing your stance, it's wise to compare both cautious and confident scenarios.

Explore 9 other fair value estimates on Gilead Sciences - why the stock might be worth over 2x more than the current price!

Build Your Own Gilead Sciences Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• Find companies with promising cash flow potential yet trading below their fair value.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com